Irodalomjegyzék
1. MARCELLIN P, ASSELAH T, BOYER N: Treatment of chronic hepatitis B. J Viral Hepat 2005, 12: 333-
345.
2. JANSSEN HL, VAN ZONNEVELD M, SENTURK S, ZEUZEM S, AKARCA US, CAKALOGLU Y AT EL: Pegylated
interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis
B: a randomised trial. Lancet, 2005, 365:123-129.
3. LAU GKK, PIRATVISUTH T, LUO KX, MARCELLIN P, THONGSAWAT S, COOKSLEY G ET AL: Peginterferon alfa2a,
lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Eng J Med
2005, 352:2682-95.
4. ERHARDT A, BLONDIN D, HAUCK K, SAGIR A, KOHNLE T, HEINTGES T, HAUSSINGER D: Response to interferon
alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than
genotype D. Gut, 2005, 54:1009-13.
5. CHAN HL, LEUNG NW, HUI AY, WONG VW, LIEW CT, CHIM AM ET AL: A randomized, controlled trial
of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and
lamivudine with lamivudine alone. Ann Intern Med, 2005, 142:240-50.
6. CHAN HL, HUI AY, WONG VW, CHIN AM, WONG M, SUNG JJ: Long-term follow-up of pegintron and
lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology, 2005,
41:1357-64.
7. HUI AZ, CHAN HL, CHEUNG AZ, COOKSLEY G, SUNG JJ. Systematic review: treatment of chronic
hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther. 2005, 22:519-28.
8. Marcellin P, Lau GKK, Bonino F et al: Peginterferon alfa-2a alone, lamivudine alone, and the
two in combinaton in patients with HBeAg-negative chronic hepatitis B. N Eng J Med. 2004,
351:1206-17.
9. DIENSTAG JL. The value and limitations of long-term nucleoside antiviral therapy in chronic
hepatitis B. J Hepatol. 2005, 42:158-162.
10. MOSKOVITZ DN, OSIOWY C, GILES E, TOMLINSON G, HEATHCOTE EJ. Response to long-term lamivudine
(up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
J Viral Hepat. 2005, 12: 398-404.
11. RIZZETTO M, TASSOPOULOS NC, GOLDIN RD, ESTEBAN R, SANTANTONIO T, HEATHCOTE J ET AL. Extended
lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2005, 42:
173-179.
12. HADZIYANNIS S, TASSOPOULOS N, HEATHCOTE J, CHANG TT, KITIS G, RIZZETTO M ET AL. Long-term therapy
with adefovir dipivoxil (ADV) for HBeAg-negative chronic hepatitis B. N Eng J Med, 2005, 352:
2673-2681.
13. PAPATHEODORIDIS GV, DIMOU E, DIMAKOPOULOS K, MANOLAKOPOULOS S, RAPTI I, KITIS G ET AL: Outcome
of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy
starting with lamivudine. Hepatology 2005, 42:121-129.
14. FUNG SK, ANDREONE P, HAN SH, REDDY KR, REGEV A, KEEFFE E ET AL. Adefovir-resistant hepatitis B
can be associated with viral rebound and hepatic decompensation. J Hepatol. 2005, 43: 937-
43.
15. MARCELLIN P, ASSELAH T. Resistance to adefovir: A new challenge in the treatment of chronic
hepatitis B. J Hepatol. 2005, 43: 920-23.
16. LAMPERTICO P, VIGANO M, MANENTI E, IAVARONEM, LUNGHI G, COLOMBO M. Adefovir rapidly suppresses
hepatitis B in HBeAg-negative patients developing genotypic resistance to laumivudine.
Hepatology 2005, 42:1414-19.
17. CHANG T, GISH RG, HADZIYANNIS S, CIANCIARA J, RIZZETTO M, SCHIFF ER ET AL. A dose-ranging study of
the effi cacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients,
Gastroenterology 2005, 129:1198-1209.
18. LAI CH, LEUNG N, TEO E, TONG M, WONG F, HANN H ET AL. A 1-year trial of telbivudine, lamivudine
and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.
Gastroenterology 2005, 129:528-536.
19. MOSLEY JW, OPERSKALSKI EA, TOBLER LH, ANDREWS WW, PHELPS B, DOCKTER J ET AL. Viral and host
factors in early hepatitis C virus infection. Hepatology 2005, 42: 86-92.
20. ZEKRY A, PATEL K, MCHUTCHISON JG. Treatment of acute hepatitis C infection: more pieces of the
puzzle? J Hepatol. 2005, 42:293-296.
21. SANTANTONIO T, FASANO M, SINISI E, GUASTADISEGNI A, CASALINO C, MAZZOLA M ET AL. Effi cacy of a
24-week course of PEG-interferon α-2b monotherapy in patients with acute hepatitis C after
failure of spontaneous clearance. J Hepatol. 2005, 42:329-33.
22. BROERS B, HELBLING B, FRANCOIS A, SCHMID P, CHUARD C, HADENGUE A ET AL. Barriers to interferon
α therapy are high in intravenous drug users than in other patients with acute hepatitis C. J
Hepatol. 2005, 42:323-328.
23. ROMERO-GOMEZ M, DEL MAR VILORIA M, ANDRADE RJ, SALMERON J, DIAGO M, FERNANDEZ-RODRIGUEZ
CM ET AL. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in
chronic hepatitis C patients. Gastroenterology. 2005, 128: 636-41.
24. CHEN L, BOROZAN I, FELD J, SUN J, TANNIS LL, COLTESCU C, HEATHCOTE J ET AL. Hepatic gene expression
discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.
Gastroenterology 2005, 128:1437-44.
25. RADKOWSKI M, GALLEGOS-OROZCO JF, JABLONSKA J, COLBY TV, WALEWSKA-ZIELECKA B, KUBICKA J ET
AL. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C.
Hepatology 2005, 41:106-114.
26. FERENCI P, FRIED M, SHIFFMAN M, SMITH C, MARINOS G, GONCALES F ET AL: Predicting sustained
virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40
KD)/ribavirin. J Hepatol. 2005, 43:425-33.
27. ZEUZEM S, PAWLOTSKY J, LUKASIEWICZ E, VON WAGNER M, GOULIS I, LURIE Y, ET AL. International, multicenter,
randomized, controlled study comparing dynamically individualized versus standard treatment
in patients with chronic hepatitis C. J Hepatol. 2005, 43: 250-57.
28. MANGIA A, SANTORO R, MINERVA N, RICCI GL, CARRETTA V, PERSICO M ET AL: Peginterferon alfa-2b and
ribavirin for 12 vs. 24 weeks in HCV genotypes 2 or 3. N Eng J Med. 2005, 352:2609-17.
29. VON WAGNER M, HUBER M, BERG T, HINRICHSEN H, RASENACK J, HEINTGES T ET AL. Peginterferon-α-2a
(40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
Gastroenterology 2005, 129:522-527.
30. KAMAL SM, EL TAWIL AA, NAKANO T, HE Q, RASENACK J, HAKAM SA ET AL. Peginterferon alfa-2b and
ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral
kinetics on sustained virological response. Gut 2005, 54: 858-66.
31. ZEUZEM S, BUTI M, FERENCI P, SPERL J, HORSMANS Y, CIANCIARA J, IBRANYI E ET AL. Effi cacy of 24 weeks
treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected
with geotype 1 and low pretreatment viremia. J Hepatol. 2006, 44:97-103.
32. LINDAHL K, STAHLE L, BRUCHFELD A, SCHVARCZ R. High-dose ribavirin in combination with standard dose
peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005, 41: 275-9.
33. LEBRAY P, NALPAS B, VALLET-PICHARD A, BROISSAND C, SOBESKY R, SERPAGGI J ET AL. The impact of
haematopoetic growth factors on the management and effi cacy of antiviral treatment in
patients with hepatitis C virus. Antivir Ther. 2005, 10: 769-76.
34. RIVKIN AM, CHAWLA S. Epoetin alfa for the treatment of combination therapy-induced hemolytic
anemia in patients infected with hepatitis C virus. Pharmacotherapy 2005, 25: 862-75.
35. CURRY MP, AFDAHL NH. Use of growth factors with antiviral therapy for chronic hepatitis C. Clin
Liver Dis. 2005, 9: 439-51.
36. SCHAEFER M, SCHWAIGER M, GARKISCH AS, PICH M, HINZPETER A, UEBELHACK R ET AL. Prevention of
interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J
Hepatol. 2005, 42:793-8.
37. WIRTH S, PIEPER-BOUSTANI H, LANG T, BALLAUFF A, KULLMER U, GERNER P ET AL. Peginterferon alfa2b
plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology
2005, 41:1013-8.
A máj | 267
268 | Gastro Update 2006
38. GONZÁLEZ-PERALTA RP, KELLY DA, HABER B, MOLLESTON J, MURRAY KF, JONAS MM ET AL. Interferon alfa2b
in combination with ribavirin for the treatment of chronic hepatitis C in children: effi cacy,
safety and pharmacokinetics. Hepatology 2005, 42:1010-18.
39. OLSSON R, BOBERG KM, SCHAFFALITSKY DE MUCKADELL O, LIDGREN S, HULTCRANTZ R, FOLVIK G ET AL. Highdose
ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized,
controlled study. Gastroenterology 2005, 129: 1464-72.
40. CORPECHOT C, CARRAT F, BAHR A, CHRETIEN Y, POUPON R, POUPON R. The effect of ursodeoxycholic
acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005, 128:
297-303.
41. RAUTIAINEN H, KARKKAINEN P, KARVONEN AL, NURMI H, PIKKARAINEN P, NUUTINEN H ET AL. Budesonide
combined with UDCA to improve histology in primary biliary cirrhosis: a three-year randomized
trial. Hepatology 2005, 41: 742-52.
42. BLENDIS L. Steroids in the management of PBC: why do we need them? Gastroenterology 2005,
129:1350-52.
43. CHAN CW, GUNSAR F, FEUDJO M, RIGAMONTI C, VLACHOGIANNAKOS J, CARPENTERJR, BURROUGHS AK.
Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years.
Aliment Pharmacol Ther. 2005, 21: 217-26.
44. FELD JJ, DINH H, ARENOVICH T, MARCUS VA, WANLESS IR, HEATHCOTE EJ. Autoimmune hepatitis: effect
of symptoms and cirrhosis on natural history and outcome. Hepatology 2005, 42: 53-62.
45. TRIPODI A, SALERNO F, CHANTARANGKUL V, CLERICI M, CAZZANIGA M, PRIMIGNANI M, MANNUCCI PM. Evidence
of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests.
Hepatology 2005, 41:553-8.
46. BOSCH J, REVERTER JC. The coagulopathy of cirrhosis: myth or reality? Hepatology 2005, 41:
434-5.
47. GROSZMANN RJ, GARCIA-TSAO G, BOSCH J, GRACE ND, BURROUGHS AK, PLANAS R, ET AL. Beta-blockers to
prevent gastroesophageal varices in patients with cirrhosis. N Eng J Med. 2005, 353: 2254-61.
48. JUTABHA R, JENSEN DM, MARTIN P, SAVIDES T, HAN S, GORNBEIN J. Randomized study comparing
banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk
esophageal varices. Gastroenterology 2005, 128: 870-81.
49. SARIN SK, WADHAVAN M, AGARWAL SR. Endoscopic variceal ligation plus propranolol versus
endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. Am J
Gastroenterol. 2005, 100: 797-804.
50. BOYER T. Primary prophylaxis for variceal bleeding: Are we there yet? Gastroenterology 2005,
128: 1120-22.
51. CHALASSANI N, BOYER T. Primary prophylaxis against variceal bleeding: beta-blockers, endoscopic
ligation, or both? Am J Gastroenterol. 2005, 100: 805-7.
52. DE LA PENA J, BRULLET E, SANCHEZ-HERNANDEZ E, RIVERO M, VERGARA M, MARTIN-LORENTE JL. Variceal
ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicentric
trial. Hepatology 2005, 41: 572-8.
53. BOYER TD, HASKAL ZJ. The role of transjugular intrahepatic portosystemic shunt in the management
of portal hypertension. AASLD practice guideline. Hepatology 2005, 41: 386-400.
54. ALBILLOS A, BANARES R, GONZÁLEZ M, CATALINA M, MOLINERO L. A meta-analysis of transjugular
intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol. 2005,
43:990-996.
55. SANYAL AJ. Pros and cons of TIPS for refractory ascites. J Hepatol. 2005, 43:924-5.
56. D’AMICO G, LUCA A, MORABITO A, MIRAGLIA R, D’AMICO M. Uncovered transjugular intrahepatic
portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005, 129:1282-
93.
57. FRANCHIS R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus
workshop on methodology of diagnosis and therapy in portal hypertnsion. J Hepatol. 2005,
43: 167-76.
58. TERRA C, GUEVARA M, TORRE A, GILABERT R, FERNÁNDEZ J, MARTIN-LLAHÍ M ET AL. Renal failure in
patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of
MELD score. Gastroenterology 2005, 129: 1944-53.
59. RUIZ-DEL-ARBOL L, MONESCILLO A, AROCENA C, VALER P, GINES P, MOREIRA V ET AL. Circulatory function
and hepatorenal syndrome in cirrhosis. Hepatology 2005, 42: 439-47.
60. ADAMS LA, LYMP JF, ST. SAUVER J, SANDERSON SO, LINDOR KD, FELDSTEIN A, ANGULO P. The natural
history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology
2005, 129: 113-21.
61. DAY CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology
2005, 129: 375-77.
62. CHALASSANI N, TEAL E, HALL SD. Effect of rosiglitazone on serum liver biochemistries in diabetic
patients wit h normal and elevated baseline liver enzymes. Am J Gastroenterol. 2005, 100:1317-
21.
